http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 23 Jun 2026 18:14:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++144++++++++Kymera+Therapeutics%2C+++++++++++++++++++Filed+by%3A+Atlas+Venture+Fund+X%2C+L.P./26680837.html si-local-file:///var/storage/secattach/20260623/26680837.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Kymera+Therapeutics%2C+++++++++++++++++++Filed+by%3A+Atlas+Venture+Fund+X%2C+L.P./26680837.html Tue, 23 Jun 2026 18:14:00 -0400 KYMR O.48213671 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Kymera+Therapeutics%2C+++++++++++++++++++Filed+by%3A+Atlas+Venture+Fund+X%2C+L.P./26680837.html si-local-file:///var/storage/secattach/20260623/26680837.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Kymera+Therapeutics%2C+++++++++++++++++++Filed+by%3A+Atlas+Venture+Fund+X%2C+L.P./26680837.html Tue, 23 Jun 2026 18:14:00 -0400 KYMR O.48213671 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Kymera+Therapeutics%2C+++++++++++++++++++Filed+by%3A+Atlas+Venture+Opportunity+Fund+I%2C+L.P./26680838.html si-local-file:///var/storage/secattach/20260623/26680838.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Kymera+Therapeutics%2C+++++++++++++++++++Filed+by%3A+Atlas+Venture+Opportunity+Fund+I%2C+L.P./26680838.html Tue, 23 Jun 2026 18:14:00 -0400 KYMR O.48213671 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Kymera+Therapeutics%2C+++++++++++++++++++Filed+by%3A+Atlas+Venture+Opportunity+Fund+I%2C+L.P./26680838.html si-local-file:///var/storage/secattach/20260623/26680838.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Kymera+Therapeutics%2C+++++++++++++++++++Filed+by%3A+Atlas+Venture+Opportunity+Fund+I%2C+L.P./26680838.html Tue, 23 Jun 2026 18:14:00 -0400 KYMR O.48213671 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Kymera+Therapeutics%2C++++++For%3A+Jun+17++Filed+by%3A+Booth+Bruce/26674635.html si-local-file:///var/storage/secattach/20260622/26674635.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Kymera+Therapeutics%2C++++++For%3A+Jun+17++Filed+by%3A+Booth+Bruce/26674635.html Mon, 22 Jun 2026 21:02:00 -0400 KYMR O.48213671 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Kymera+Therapeutics%2C++++++For%3A+Jun+17++Filed+by%3A+Booth+Bruce/26674635.html si-local-file:///var/storage/secattach/20260622/26674635.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Kymera+Therapeutics%2C++++++For%3A+Jun+17++Filed+by%3A+Booth+Bruce/26674635.html Mon, 22 Jun 2026 21:02:00 -0400 KYMR O.48213671 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Kymera+Therapeutics%2C++++++For%3A+Jun+17++Filed+by%3A+Booth+Bruce/26674634.html si-local-file:///var/storage/secattach/20260622/26674634.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Kymera+Therapeutics%2C++++++For%3A+Jun+17++Filed+by%3A+Booth+Bruce/26674634.html Mon, 22 Jun 2026 21:01:00 -0400 KYMR O.48213671 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Kymera+Therapeutics%2C++++++For%3A+Jun+17++Filed+by%3A+Booth+Bruce/26674634.html si-local-file:///var/storage/secattach/20260622/26674634.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Kymera+Therapeutics%2C++++++For%3A+Jun+17++Filed+by%3A+Booth+Bruce/26674634.html Mon, 22 Jun 2026 21:01:00 -0400 KYMR O.48213671 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Kymera+Therapeutics%2C++++++For%3A+Jun+22++Filed+by%3A+Goodman+Noah/26674281.html si-local-file:///var/storage/secattach/20260622/26674281.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Kymera+Therapeutics%2C++++++For%3A+Jun+22++Filed+by%3A+Goodman+Noah/26674281.html Mon, 22 Jun 2026 17:47:00 -0400 KYMR O.48213671 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Kymera+Therapeutics%2C++++++For%3A+Jun+22++Filed+by%3A+Goodman+Noah/26674281.html si-local-file:///var/storage/secattach/20260622/26674281.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Kymera+Therapeutics%2C++++++For%3A+Jun+22++Filed+by%3A+Goodman+Noah/26674281.html Mon, 22 Jun 2026 17:47:00 -0400 KYMR O.48213671 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Kymera+Therapeutics%2C+++++++++++++++++++Filed+by%3A+Atlas+Venture+Opportunity+Fund+I%2C+L.P./26674197.html si-local-file:///var/storage/secattach/20260622/26674197.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Kymera+Therapeutics%2C+++++++++++++++++++Filed+by%3A+Atlas+Venture+Opportunity+Fund+I%2C+L.P./26674197.html Mon, 22 Jun 2026 17:29:00 -0400 KYMR O.48213671 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Kymera+Therapeutics%2C+++++++++++++++++++Filed+by%3A+Atlas+Venture+Opportunity+Fund+I%2C+L.P./26674197.html si-local-file:///var/storage/secattach/20260622/26674197.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Kymera+Therapeutics%2C+++++++++++++++++++Filed+by%3A+Atlas+Venture+Opportunity+Fund+I%2C+L.P./26674197.html Mon, 22 Jun 2026 17:29:00 -0400 KYMR O.48213671 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Kymera+Therapeutics%2C+++++++++++++++++++Filed+by%3A+Atlas+Venture+Fund+X%2C+L.P./26674192.html si-local-file:///var/storage/secattach/20260622/26674192.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Kymera+Therapeutics%2C+++++++++++++++++++Filed+by%3A+Atlas+Venture+Fund+X%2C+L.P./26674192.html Mon, 22 Jun 2026 17:28:00 -0400 KYMR O.48213671 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Kymera+Therapeutics%2C+++++++++++++++++++Filed+by%3A+Atlas+Venture+Fund+X%2C+L.P./26674192.html si-local-file:///var/storage/secattach/20260622/26674192.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Kymera+Therapeutics%2C+++++++++++++++++++Filed+by%3A+Atlas+Venture+Fund+X%2C+L.P./26674192.html Mon, 22 Jun 2026 17:28:00 -0400 KYMR O.48213671 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Kymera+Therapeutics%2C+++++++++++++++++++Filed+by%3A+Goodman+Noah/26673801.html si-local-file:///var/storage/secattach/20260622/26673801.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Kymera+Therapeutics%2C+++++++++++++++++++Filed+by%3A+Goodman+Noah/26673801.html Mon, 22 Jun 2026 16:47:00 -0400 KYMR O.48213671 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Kymera+Therapeutics%2C+++++++++++++++++++Filed+by%3A+Goodman+Noah/26673801.html si-local-file:///var/storage/secattach/20260622/26673801.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Kymera+Therapeutics%2C+++++++++++++++++++Filed+by%3A+Goodman+Noah/26673801.html Mon, 22 Jun 2026 16:47:00 -0400 KYMR O.48213671 http://www.streetinsider.com/Rumors/Truist+Securities+Reiterates+Buy+Rating+on+Kymera+Therapeutics+%28KYMR%29+Following+Sector+Deal/26671618.html <p>Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $116.00 price target on Kymera Therapeutics (NASDAQ: KYMR) after AbbVie announced it would acquire Apogee for $10.9B, a ~50% premium to last Thursday's closing price.</p><p>The analyst commented, "This morning, AbbVie (ABBV, NR) announced it would acquire Apogee (APGE, Hold, Brill) for $10.9B, a ~50% premium to last Thursday's closing price. APGE's zumilokibart (IL-13) is being studied as a subcutaneous injection given once every three or six months in AD (Ph3 planned start 2H26), asthma (Ph2b start 1H27), and eosinophilic esophagitis (Ph2a start 2H26). We see this as a positive read-through http://www.streetinsider.com/Rumors/Truist+Securities+Reiterates+Buy+Rating+on+Kymera+Therapeutics+%28KYMR%29+Following+Sector+Deal/26671618.html Mon, 22 Jun 2026 11:24:33 -0400 KYMR http://www.streetinsider.com/Analyst+Comments/Truist+Securities+Reiterates+Buy+Rating+on+Kymera+Therapeutics+%28KYMR%29+Following+Sector+Deal/26671618.html <p>Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $116.00 price target on Kymera Therapeutics (NASDAQ: KYMR) after AbbVie announced it would acquire Apogee for $10.9B, a ~50% premium to last Thursday's closing price.</p><p>The analyst commented, "This morning, AbbVie (ABBV, NR) announced it would acquire Apogee (APGE, Hold, Brill) for $10.9B, a ~50% premium to last Thursday's closing price. APGE's zumilokibart (IL-13) is being studied as a subcutaneous injection given once every three or six months in AD (Ph3 planned start 2H26), asthma (Ph2b start 1H27), and eosinophilic esophagitis (Ph2a start 2H26). We see this as a positive read-through http://www.streetinsider.com/Analyst+Comments/Truist+Securities+Reiterates+Buy+Rating+on+Kymera+Therapeutics+%28KYMR%29+Following+Sector+Deal/26671618.html Mon, 22 Jun 2026 11:24:33 -0400 KYMR http://www.streetinsider.com/Hot+Comments/Truist+Securities+Reiterates+Buy+Rating+on+Kymera+Therapeutics+%28KYMR%29+Following+Sector+Deal/26671618.html <p>Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $116.00 price target on Kymera Therapeutics (NASDAQ: KYMR) after AbbVie announced it would acquire Apogee for $10.9B, a ~50% premium to last Thursday's closing price.</p><p>The analyst commented, "This morning, AbbVie (ABBV, NR) announced it would acquire Apogee (APGE, Hold, Brill) for $10.9B, a ~50% premium to last Thursday's closing price. APGE's zumilokibart (IL-13) is being studied as a subcutaneous injection given once every three or six months in AD (Ph3 planned start 2H26), asthma (Ph2b start 1H27), and eosinophilic esophagitis (Ph2a start 2H26). We see this as a positive read-through http://www.streetinsider.com/Hot+Comments/Truist+Securities+Reiterates+Buy+Rating+on+Kymera+Therapeutics+%28KYMR%29+Following+Sector+Deal/26671618.html Mon, 22 Jun 2026 11:24:33 -0400 KYMR http://www.streetinsider.com/SEC+Filings/Form++144++++++++Kymera+Therapeutics%2C+++++++++++++++++++Filed+by%3A+Atlas+Venture+Opportunity+Fund+I%2C+L.P./26667436.html si-local-file:///var/storage/secattach/20260618/26667436.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Kymera+Therapeutics%2C+++++++++++++++++++Filed+by%3A+Atlas+Venture+Opportunity+Fund+I%2C+L.P./26667436.html Thu, 18 Jun 2026 17:36:00 -0400 KYMR O.48213671 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Kymera+Therapeutics%2C+++++++++++++++++++Filed+by%3A+Atlas+Venture+Opportunity+Fund+I%2C+L.P./26667436.html si-local-file:///var/storage/secattach/20260618/26667436.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Kymera+Therapeutics%2C+++++++++++++++++++Filed+by%3A+Atlas+Venture+Opportunity+Fund+I%2C+L.P./26667436.html Thu, 18 Jun 2026 17:36:00 -0400 KYMR O.48213671 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Kymera+Therapeutics%2C+++++++++++++++++++Filed+by%3A+Atlas+Venture+Fund+X%2C+L.P./26667433.html si-local-file:///var/storage/secattach/20260618/26667433.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Kymera+Therapeutics%2C+++++++++++++++++++Filed+by%3A+Atlas+Venture+Fund+X%2C+L.P./26667433.html Thu, 18 Jun 2026 17:35:00 -0400 KYMR O.48213671 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Kymera+Therapeutics%2C+++++++++++++++++++Filed+by%3A+Atlas+Venture+Fund+X%2C+L.P./26667433.html si-local-file:///var/storage/secattach/20260618/26667433.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Kymera+Therapeutics%2C+++++++++++++++++++Filed+by%3A+Atlas+Venture+Fund+X%2C+L.P./26667433.html Thu, 18 Jun 2026 17:35:00 -0400 KYMR O.48213671 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Kymera+Therapeutics%2C+++++++++++++++++++Filed+by%3A+Atlas+Venture+Fund+X%2C+L.P./26661013.html si-local-file:///var/storage/secattach/20260617/26661013.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Kymera+Therapeutics%2C+++++++++++++++++++Filed+by%3A+Atlas+Venture+Fund+X%2C+L.P./26661013.html Wed, 17 Jun 2026 17:26:00 -0400 KYMR O.48213671 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Kymera+Therapeutics%2C+++++++++++++++++++Filed+by%3A+Atlas+Venture+Fund+X%2C+L.P./26661013.html si-local-file:///var/storage/secattach/20260617/26661013.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Kymera+Therapeutics%2C+++++++++++++++++++Filed+by%3A+Atlas+Venture+Fund+X%2C+L.P./26661013.html Wed, 17 Jun 2026 17:26:00 -0400 KYMR O.48213671